The Prime Minister had inaugurated the national Animal Disease Control Program at Uttar Pradesh’s Mathura. It aims to eradicate 2 major diseases affecting the Indian livestock- Foot and Mouth Disease/ FMD and the Brucellosis. Both these diseases are of major concern, especially to the dairy industry.
The member nations of the WHO Regional Committee for South-East Asia have postponed the deadline for achieving the eradication of measles and rubella. India accounts for 36% of the global measles cases. The major campaign undertaken by the Indian government is currently facing challenges due to the reluctance of the public and also because of its vast coverage. The deadline has been postponed mainly due to these hindrances. The government needs to address these issues to make India free from the two major childhood killers – measles and rubella
As per the records, the world’s one-third of the rabies deaths are from India. According to the Health Ministry, India is the hotbed for human rabies. India is currently facing a shortage of ant-rabies vaccines in certain part of the country. The National Pharmaceutical Pricing Authority has asked the manufacturers and marketers to rush stocks to the areas that are suffering from a severe shortage of anti-rabies vaccines. In India, approximately 20,000 deaths are caused due to vaccine-preventable fatality each year. Therefore, rapid response to this issue is a need of the hour.
National Medical Commission Bill, 2019 was recently passed in the Rajya Sabha. This bill is under public scrutiny due to its vague and unclear provisions, underrepresentation of the medical community and for not being student-friendly.
Poor sanitation is a primary cause of diseases worldwide = improving sanitation can have a beneficial impact on health both in households as well as communities. In order to meet the sanitation need, the government had launched the Swachh Bharat Mission in 2014. Since then, SBM became the world’s largest sanitation program by changing the behaviour of hundreds of millions of people with respect to toilet access and usage. However, there are also concerns regarding the overreporting of data, actual usage of toilets, etc. which we will discuss in this article.
Updates * What is the National Health Protection Mission (NHPM)? NHPS is a health insurance …
The New Drugs and Clinical Trial Rules, 2019 released by the government seeks to enable faster approvals and to cut down on red tape with respect to the clinical trials in India. It seeks to promote clinical research in India by providing for a predictable, transparent and effective regulation for clinical trials and by guaranteeing faster accessibility of new drugs to the Indian population. Thus it has the potential to reinvigorate the clinical research industry, which was almost on its death bed a few years ago.
This article answers the following questions in an analytical manner.
- What are clinical trials?
- What is the need for clinical trials?
- How Clinical trials are conducted?
- Why is India a popular destination for Clinical trials?
- What is the regulatory mechanism for Clinical Trials in India?
- What are the key Issues regarding Clinical Trials in India?
- What are the measures taken by the government to solve those issues?
- What are the features and significances of the new rules of 2019?
- What are the suggestions to further improve the scenario?
The Ministry of Chemicals & Fertilizers has recently released the Drugs (Prices Control) Amendment Order, 2019 which prescribes that the drugmaker who has brought in an innovative patented drug will be exempt from the price control rules for 5 years from the date of marketing. It is meant to strike the right balance between consumer and producer interests. However, it falls short of addressing certain concerns regarding the drug pricing regulation in India.